Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

por Horie, Yoshiharu, Hayashi, Naoyuki, Dugi, Klaus, Takeuchi, Masahiro
Publicado 2009

The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk

por Kempf, Kerstin, Martin, Stephan, Döhring, Carmen, Dugi, Klaus, Wolfram von Wolmar, Carolin, Haastert, Burkhard, Schneider, Michael
Publicado 2013

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

por Heise, Tim, Seman, Leo, Macha, Sreeraj, Jones, Peter, Marquart, Alexandra, Pinnetti, Sabine, Woerle, Hans J., Dugi, Klaus
Publicado 2013

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

por Zimdahl, Heike, Ittrich, Carina, Graefe-Mody, Ulrike, Boehm, Bernhard O., Mark, Michael, Woerle, Hans-Juergen, Dugi, Klaus A.
Publicado 2014

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

por Rauch, Thomas, Graefe-Mody, Ulrike, Deacon, Carolyn F., Ring, Arne, Holst, Jens J., Woerle, Hans-Juergen, Dugi, Klaus A., Heise, Tim
Publicado 2012

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design

por Melloni, Chiara, Slovin, Susan F., Blemings, Allan, Goodman, Shaun G., Evans, Christopher P., Nilsson, Jan, Bhatt, Deepak L., Zubovskiy, Konstantin, Olesen, Tine K., Dugi, Klaus, Clarke, Noel W., Higano, Celestia S., Roe, Matthew T.
Publicado 2020